Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 10/20 | 0.36 |
| ▸ | CDK2 | P24941 | 9/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513950 | 0.91 | CDK4 (0.40) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL8512741 | 0.90 | CDK4 (0.49) | LCKKDRCDK4CDK2FGFR1 | |
| SCHEMBL9609438 | 0.88 | SRC (0.41) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL8511945 | 0.88 | SRC (0.48) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL9609437 | 0.88 | WEE1 (0.37) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL213088 | 0.87 | SRC (0.49) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL8509293 | 0.85 | WEE1 (0.40) | WEE1SRCLCKKDRCDK2 | |
| SCHEMBL8513087 | 0.84 | JAK2 (0.40) | WEE1SRCLCKKDRCDK4 | |
| SCHEMBL8510013 | 0.82 | WEE1 (0.38) | WEE1SRCLCKKDRFGFR1 | |
| SCHEMBL8513897 | 0.81 | CAMK2D (0.44) | WEE1SRCLCKKDRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | WEE1 1/4885SRC 546/4885LCK 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.